BTG International Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Approved for marketing

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

Earlier

Feb 13, 2024FDAAurlumyn — AURLUMYN

Jun 6, 2023TrialA French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

Nov 25, 2020FDADANYELZA — DANYELZA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

VistogardAug 17, 2027 AurlumynAug 6, 2041 AurlumynJul 18, 2044

Regulatory

Regulatory Timeline

20051 event

FDADec 8

Aurlumyn — VENTAVIS

Application NDA021779 (NDA)

20061 event

FDADec 15

Cyanokit — CYANOKIT

Application NDA022041 (NDA)

20121 event

FDAJan 17

VORAXAZE — VORAXAZE

Application BLA125327 (BLA)

20152 events

FDADec 11

Vistogard — VISTOGARD

Application NDA208159 (NDA)

FDASep 4

Vistogard — XURIDEN

Application NDA208169 (NDA)

20201 event

FDANov 25

DANYELZA — DANYELZA

Application BLA761171 (BLA)

20241 event

FDAFeb 13

Aurlumyn — AURLUMYN

Application NDA217933 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)